Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention

Sara M. Centuori, Carlos Caulin, Julie E. Bauman

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


To date, there is no FDA-approved chemoprevention approach for tobacco-related HNSCC. Effective chemoprevention approaches validated in sufficiently powered randomized trials are needed to reduce the incidence and improve survival. In this review, we recap the challenges encountered in past chemoprevention trials and discuss emerging approaches, with major focus on green chemoprevention, precision prevention, and immunoprevention. As our current depth of knowledge expands in the arena of cancer immunotherapy, the field of immunoprevention is primed for new discoveries and successes in cancer prevention.

Original languageEnglish (US)
Article number52
JournalCurrent Treatment Options in Oncology
Issue number6
StatePublished - Jun 2021


  • Chemoprevention
  • Head and neck squamous cell carcinoma (HNSCC)
  • Immunoprevention
  • Smoking

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this